CRVO Share Price Performance
US$7.25
-3.67 (-33.61%)
Price US$7.25
Share Pricen/a
CervoMed Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
CRVO Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
CervoMed Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -2.77
- -15.05%
- -415.36%
- 0%
About CRVO
- Founded
- 2010
- Employees
- 15
- CEO
- WebsiteView website
CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. It is being evaluated in a Phase 2b study in patients with DLB. The company develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
